Madrigal Pharmaceuticals
Open
$501.23
Prev. Close
$500.97
High
$502.54
Low
$500.89
Market Snapshot
$11.5B
-37.2
-21.99
$180.13M
915
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The firm is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The firm is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Recently from Cashu
Madrigal Pharmaceuticals' Rezdiffra Data Promises Advances in Liver Health and Cardiovascular Risks
Madrigal Pharmaceuticals (Ticker: MDGL) is currently receiving renewed attention due to the presentation of promising data regarding its drug Rezdiffra at the EASL Congress 2026. This presentation sho…
Madrigal Pharmaceuticals' Rezdiffra Data Generates Investor Excitement Ahead of EASL Congress 2026.
Madrigal Pharmaceuticals (Ticker: MDGL) recently unveils compelling data on its drug Rezdiffra, aimed at treating liver diseases, which is generating significant interest in the pharmaceutical communi…
Madrigal Pharmaceuticals: Mixed Analyst Sentiment Highlights Uncertainty in Future Potential
Madrigal Pharmaceuticals Faces Mixed Analyst Sentiment Amid Uncertainty Madrigal Pharmaceuticals currently captures attention with its dual narrative of optimism and skepticism emerging from recent an…
Madrigal Pharmaceuticals Navigates Analyst Divergence Amid Regulatory Challenges and Clinical Trials
Madrigal Pharmaceuticals Faces Divergent Analyst Sentiment Amid Regulatory Uncertainty Madrigal Pharmaceuticals stands at a crossroads as it navigates a complex landscape of investor expectations and…